Leap Therapeutics to Present Preclinical and Clinical Data at 2017 AACR Annual Meeting
March 01 2017 - 6:40PM
Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company
developing targeted and immuno-oncology therapeutics, today
announced preclinical and clinical data presentations will be made
during the 2017 American Association for Cancer Research (AACR)
Annual Meeting, being held April 1 - 5, 2017, in Washington,
D.C. Data on TRX518 will be presented as an oral presentation
in a clinical trials plenary session by Roberta Zappasodi, Ph.D.,
Parker Institute Scholar and Research Scholar in the Ludwig
Collaborative Laboratory at Memorial Sloan Kettering Cancer Center
from the lab of Taha Merghoub, Ph.D., Associate Attending Lab
Member of the Ludwig Collaborative Laboratory at the Memorial Sloan
Kettering Cancer Center and Jedd Wolchok, M.D. Ph.D., Chief of
Melanoma and Immunotherapeutics Service at Memorial Sloan Kettering
Cancer Center.
Abstract Number and Title: #CT018, Intratumor
and peripheral Treg modulation as a pharmacodynamic biomarker of
the GITR agonist antibody TRX-518 in the first in-human
trialSession Title: Immuno-oncology Biomarkers in Clinical
TrialsSession Date and Time: Sunday Apr 2, 2017 3:28 PM - 3:43
PMSession Location: Hall D-E, Level 2, Washington Convention
Center
Abstract Number and Title: #369, Therapeutic
targeting of the Wnt antagonist DKK1 with a humanized monoclonal
antibody in oncology indicationsSession Title: Cell Growth
Signaling Pathways 2Session Date and Time: Sunday Apr 2, 2017 1:00
PM - 5:00 PMSession Location: Convention Center, Halls A-C, Poster
Section 15
About Leap TherapeuticsLeap
Therapeutics’ (NASDAQ:LPTX) most advanced clinical candidate,
DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1
(DKK1) protein. DKN-01 is in clinical trials in patients with
gastroesophageal cancer in combination with paclitaxel and in
patients with biliary tract cancers in combination with gemcitabine
and cisplatin. DKN-01 has demonstrated single agent activity in
non-small cell lung cancer patients. Leap’s second clinical
candidate, TRX518, is a novel, humanized GITR agonist monoclonal
antibody designed to enhance the immune system’s anti-tumor
response. For more information about Leap Therapeutics, visit
http://www.leaptx.com or our public filings with the SEC that are
available via EDGAR at http://www.sec.gov or via
http://www.investors.leaptx.com/.
FORWARD LOOKING STATEMENTS
Some of the statements in this release are
forward looking statements within the meaning of Section 27A of the
Securities Act of 1933, Section 21E of the Securities Exchange Act
of 1934 and the Private Securities Litigation Reform Act of 1995,
which involve risks and uncertainties. These statements relate to
future events of Leap’s development of DKN-01, TRX518, and other
programs, future expectations, plans and prospects. Although Leap
believes that the expectations reflected in such forward-looking
statements are reasonable as of the date made, expectations may
prove to have been materially different from the results expressed
or implied by such forward-looking statements. Leap has attempted
to identify forward looking statements by terminology including
‘‘believes,’’ ‘‘estimates,’’ ‘‘anticipates,’’ ‘‘expects,’’
‘‘plans,’’ ‘‘projects,’’ ‘‘intends,’’ ‘‘potential,’’ ‘‘may,’’
‘‘could,’’ ‘‘might,’’ ‘‘will,’’ ‘‘should,’’ ‘‘approximately’’ or
other words that convey uncertainty of future events or outcomes to
identify these forward-looking statements. These statements are
only predictions and involve known and unknown risks,
uncertainties, and other factors. Any forward looking statements
contained in this release speak only as of its date. We undertake
no obligation to update any forward-looking statements contained in
this release to reflect events or circumstances occurring after its
date or to reflect the occurrence of unanticipated events.
CONTACT
Douglas E. Onsi
Chief Financial Officer
Leap Therapeutics, Inc.
donsi@leaptx.com
617-714-0360
Leap Therapeutics (NASDAQ:LPTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Leap Therapeutics (NASDAQ:LPTX)
Historical Stock Chart
From Apr 2023 to Apr 2024